HEAL is trading 3.06% up at $29.77, with broader market strength the likeliest available context, though no direct cause is established.

  • The supplied context shows the S&P 500 up 0.82% and Nasdaq up 1.26%.
  • HEAL’s holdings span healthcare technology companies. Eli Lilly’s EloraTZP Phase 2 results were reported September 30 and are not a new HEAL-specific catalyst for October 5.